Pazenir - direct healthcare professional communication (DHPC)

paclitaxel

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Pazenir® (paclitaxel formulated as albumin bound nanoparticles) 5 mg/ml powder for dispersion for infusion: temporary supply shortage

Dissemination date: 24/01/2023

Key facts

• Medicine name:
  Pazenir
• Active substance:
  paclitaxel
• Therapeutic area (MeSH):
  Breast Neoplasms
• Procedure number:
  EMEA/H/C/004441
• DHPC type:
  Medicine shortage
• Human ATC codes:
  L01CD01
• Dissemination date:
  24/01/2023